The NICE has issued final draft guidance recommending Tezspire for use within NHS England and NHS Wales as an add-on maintenance therapy in adult and adolescent patients aged ≥12yrs. with sev. asthma
The recommendation was based on the (PATHFINDER) program incl. the P-III trial (NAVIGATOR) evaluating tezepelumab vs PBO which demonstrated a 56% reduction in AAER (0.93 vs 2.10). The results were published in the NEJM
In patients with a blood eosinophil count of <300 cells/ µL, the annualized rate was 1.02 vs 1.73 & improvements in 2EPs over baseline, incl. lung function, asthma control & health-related QoL, were well tolerated and resulted in reductions in asthma exacerbations in (NAVIAGTOR) & (SOURCE) trials with no clinical differences in safety results
Ref: Pharmiweb | Image: AstraZeneca
Related News:- AstraZeneca’s Tezspire (tezepelumab) Receives the EU Approval for the Treatment of Severe Asthma
